Terapia gênica do glioblastoma multiforme

Amanda Rêbelo Sampaio Marreiros, Laysa Layna Ribeiro Lima, Marcela Mendes Bandeira, Daniela Moura Parente

Resumo


O objetivo desse estudo é apresentar as características do glioblastoma multiforme, em uma revisão literária que foca na terapia gênica para esse tipo de tumor. A coleta de dados foi feita nas seguintes bases de dados: Biblioteca Virtual da Saúde (BVS): Scielo (Scientific Eletronic Library Online), Literatura LatinoAmericana e do Caribe em Ciências da Saúde (LILACS) com artigos da língua inglesa, espanhola e portuguesa. Os gliomas são tumores originados das células da glia. Os gliomas malignos, ou seja, mais agressivos, são divididos em neoplasias anaplásicas e o glioblastoma multiforme (GBM). O GBM é uma neoplasia de origem astrocítica classificada no grau IV.

Palavras-chave


Glioblastoma multiforme, Terapia gênica, Temozolamida.

Referências


Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int.201; 107(45):799-807.

Loew S, Schmidt U, Unterberg A, Halatsch ME. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem. 2009;9:703-15.

Trindade V, Picarelli H, Figueredo E, Teixeira M. Gliomas: marcadores tumorais e prognóstico.

Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 2012;14(Suppl5): v1-v49.

Loew S, Schmidt U, Unterberg A, Halatsch ME. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem. 2009; 9:703-15.

Rossi M, Magnoli L, Miracco C, Mori E, Tosi P, Pirtoli L, et al. β-catenin and G|i1 are prognostic makers in glioblastoma. Cancer Bio| Ther.2011;11(8):753-61.

Osborne RH, Houben MP, Tijssen CC, Coebergh JW, Van CM. The genetic epidemiology of glioma. Neurology. v. 27. p. 1751- 5, 2001.

Dresemann G. Temozolomide in malignant glioma. Onco Targets Ther. v. 3. p.139– 146, 2010.

Ohka F, Natsume A, Wakabayashi, T. Current Trends in Targeted Therapies for Glioblastoma Multiforme. Neurology Research International v. 3. p. 124-137, 2012.

Mrugala M M. Advances and Challenges in the Treatment of Glioblastoma: A Clinician’s Perspective. Discov Med v.15. p.221-230, 2013.

Ohgaki H, kleihues P. Epidemiology and etiology of gliomas. ActaNeuropathol. v. 109. p. 93–108, 2005.

Holland EC. Curr. Opin. Neurol. 2011. Padros MD, Russo C. Chemotherapy of brain tumors. Semin. Surg. Oncol. v. 14. p. 88-95, 1998.

Sathomsumete S, Reardon DA, Desjardins A, Quinn JA, Vredenbrugh JJ, RICH JN. Molecularly targeted therapy for magnant glioma. Cancer. v. 110. p. 13-24, 2007.

Kesari S. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatment. Semin Oncol. V. 38. P. 12-20, 2011.

Padros M. Temozolomide in combination with other cytotoxic agents. Semin. Oncol. v. 28. p. 24-33, 2001.

Ahmadloo N, Kani Aa, Mohammadianpanah M, Nasrolahi H, Omidvari S, Mosalaei A, Ansari M. Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Canc Inst.

v. 25. p. 21–30, 2013.

Von Deimling A, Korshunov A, Hartmann C, The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011.

Schold SC Jr, Kokkinakis DM, Chang SM, Berger MS, Hess KR, Schiff D, et al. O6- bencylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. Neuro Oncol. 2004.

Ducray F, Idbaih A, De Reynies A, Bieche I, Thillet J, Mokhtari K, et al.

Anaplasticoligodendrogliomas with 1p19q codeletion have a proneural gene expression profile, Mol Cancer. 2008.

Ducray F, Idbaih A, De Reynies A, Bieche I, Thillet J, Mokhtari K, et al. Anaplasticoligodendrogliomas with 1p19q codeletion have a proneural gene expression profile, Mol Cancer. 2008.


Texto completo: PDF

Apontamentos

  • Não há apontamentos.